Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tiotropium · 3 trials · 1 indication
maximum plasma concentration
measured by noncompartmental analysis
noncompartmental analysis
| Arm | Type | Description |
|---|---|---|
| Test Product 1 Tiotropium | EXPERIMENTAL | 4 inhalations |
| Test Product 2 Tiotropium | EXPERIMENTAL | 4 inhalations |
| Test Product 3 Tiotropium | EXPERIMENTAL | 4 inhalations |
| Reference Tiotropium | ACTIVE_COMPARATOR | 2 inhalations |
| Test product A | EXPERIMENTAL | tiotropium |
| Test product B | EXPERIMENTAL | tiotropium |
| reference product | ACTIVE_COMPARATOR | tiotropium |
| test product C | EXPERIMENTAL | tiotropium |
| Commercial product D | ACTIVE_COMPARATOR | tiotropium |
| commercial product E | ACTIVE_COMPARATOR | tiotropium |
| Name | Type | Description |
|---|---|---|
| Tiotropium | DRUG | - |
Inclusion Criteria: * Healthy Volunteer * Willing and able to give informed consent * Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic * Subjects must agree to use an adequate method of contraception ...
Tiotropium is a small molecule being studied in healthy volunteers. It is delivered via inhaler products, and the clinical trials focus on comparing the pharmacokinetics of tiotropium from test inhaler products with reference products. The drug is currently in Phase 1 clinical development.
Tiotropium is being developed by Solventum Corporation, which trades under the ticker SOLV. The company is conducting Phase 1 clinical trials to evaluate the pharmacokinetics of tiotropium delivered from different inhaler products in healthy volunteers.
Tiotropium is in Phase 1 clinical development. All three completed trials are Phase 1 studies involving healthy volunteers. These trials are designed to compare the pharmacokinetics of tiotropium delivered from test inhaler products with reference products.
Tiotropium has been studied in three completed Phase 1 clinical trials: NCT02627625, NCT02676297, and NCT03302065. Each trial enrolled healthy volunteers aged 18 years and older, with enrollment numbers of 31, 26, and 38 participants, respectively. The trials were conducted in the United Kingdom.
Tiotropium is an investigational drug currently in Phase 1 clinical development. It has not been approved by the FDA, as it is still being studied in clinical trials. The completed trials focused on pharmacokinetic comparisons in healthy volunteers, which are early-stage studies.
Tiotropium is delivered via inhaler products. The clinical trials compare the pharmacokinetics of tiotropium from test inhaler products with reference products. These studies are conducted in healthy volunteers to assess how the drug is absorbed and processed by the body.